Project Grant R21AG085012
- This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) to the Regents of the University of Michigan provides $445,144 in funding to examine the relationship between blood-based mitochondrial bioenergetic capacity in frozen samples, socioeconomic position, and physical functioning in older adults. The key objectives are to: 1) Test the reliability and validity of using the innovative Respirometry in Frozen Samples (RIFS) method to measure systemic markers...
- Summary The Oklahoma Medical Research Foundation received a $2.6 million Project Grant from the National Institute on Aging under the Aging Research program (CFDA 93.866), awarded September 15, 2025, with a completion date of August 31, 2029. The grant funds basic neuroscience research investigating the role of mitochondrial AMP-activated protein kinase (AMPK) signaling in Alzheimer's disease-related neuronal dysfunction. Specifically, the research seeks to elucidate how AMPK activation at the...
- This $151,000 Project Grant, awarded by the National Institute of General Medical Sciences (NIGMS) under the Biomedical Research and Research Training program (CFDA 93.859), supports research focused on developing a novel class of proteolysis targeting chimeras (PROTACs) designed to degrade poly(ADP-ribose) polymerase-1 (PARP-1) in diseased human cells. The research addresses limitations of existing PARP-1 inhibitors by creating degrader molecules that downregulate PARP-1 activity, effectively...
- Federal Project Grant Award Summary The University of Texas Southwestern Medical Center received a $125,000 Project Grant award from the National Institute of General Medical Sciences (NIGMS) under the Biomedical Research and Research Training program (CFDA 93.859), effective August 15, 2025, through July 31, 2027. This award supports fundamental biomedical research investigating novel mechanisms of purine regulation and their roles in human pathophysiology. The research focuses on elucidating...
- This federal Project Grant award from the National Institute of General Medical Sciences (NIGMS), under the Biomedical Research and Research Training program (CFDA 93.859), provides $447,337 to Ball State University to conduct research on the regulator MITONEET and its role in cellular redox homeostasis and signaling. The research aims to investigate how the electronic properties and stability of the MITONEET [2Fe-2S] cluster contribute to the metabolism of sulfur-containing molecules and the...
- This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) to the University of Washington provides $485,375 to investigate the mechanisms underlying reduced resilience and adaptability of aging skeletal muscle. The project aims to determine whether increased mitochondrial redox stress drives the impairment of redox stress response signaling and declining muscle function with age. The researchers will use skeletal muscle contraction as a model to examine the...
- This federal Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $419,056 to Texas A&M AgriLife Research to develop nanoparticle-based therapies to improve mitochondrial function and treat metabolic disease in post-menopausal women. The research aims to determine if two distinct nanoparticles - molybdenum disulfide (MoS2) nanoflowers and mitochondria-targeted estradiol (Mito-E2) - can enhance mitochondrial function and reduce oxidative stress in...
- This National Science Foundation (NSF) project grant, awarded under the Biological Sciences program (CFDA 47.074), will provide $1,225,175.00 to support a 3-year study at Wayne State University on the adaptation of the cytochrome c oxidase enzyme in response to hypoxic (low oxygen) conditions in systemic vascular cells. The key objectives are to: 1) characterize the dynamic regulation of cytochrome c oxidase subunit isoform composition in systemic pericytes and vascular cells under chronic...
- Federal Project Grant Award Summary The National Institute on Aging awarded $740,075 to Weill Medical College of Cornell University on September 15, 2025, under the Aging Research program (CFDA 93.866) to support a five-year research project extending through June 30, 2030. This project grant funds scientific research investigating the mechanisms by which Complex III-derived reactive oxygen species (CIII-ROS) influence mitochondrial-nuclear crosstalk in Alzheimer's disease and related dementias....
- This Project Grant award from the National Institute of Biomedical Imaging and Bioengineering (NIBIB), under the Discovery and Applied Research for Technological Innovations to Improve Human Health program (CFDA 93.286), is supporting research to develop mitochondrial-targeting exosomes (MTEs) containing anti-inflammatory microRNAs (MTE-miRNAs) to treat neuroinflammation. The $469,500 award to Michigan Technological University aims to restore mitochondrial function, reduce oxidative stress,...
NAD(P)H QUINONE OXIDOREDUCTASE 1 (NQO1)-MEDIATED BYPASS OF MITOCHONDRIAL ELECTRON TRANSPORT CHAIN WITH ARTIFICIAL AND ENDOGENOUS SUBSTRATES - ABSTRACT A WIDE RANGE OF RARE AND COMMON DISEASES ARE LINKED TO MITOCHONDRIAL DYSFUNCTION AND ASSOCIATED REDOX IMBALANCE. RESTORATION OF THE UNDERLYING REDOX IMBALANCE BY DECREASING THE CELLULAR NADH/NAD+ RATIO COULD BE SEEN AS AN EXTREMELY USEFUL GENERALIZABLE STRATEGY IN THE CONTEXT OF MULTIPLE DISEASE STATES. NAD(P)H:QUINONE OXIDOREDUCTASE 1 (NQO1) IS A SOLUBLE CYTOPLASMIC ENZYME THAT HAS BEEN MOSTLY VIEWED AS A XENOBIOTIC- METABOLIZING ENZYME, OR A BIOACTIVATOR OF CANCER DRUGS AT THE EXPENSE OF REDUCING EQUIVALENTS OF NAD(P)H. INTERESTINGLY, SOME OF NQO1 ARTIFICIAL SUBSTRATES, MOSTLY NAPHTHOQUINONES, WHEN REDUCED ARE CAPABLE OF SUBSEQUENTLY DONATING THEIR ELECTRONS TO THE MITOCHONDRIAL ELECTRON TRANSPORT CHAIN DOWNSTREAM OF COMPLEX I. THIS NQO1-MEDIATED ALTERNATIVE ELECTRON TRANSFER IS THEREFORE AN ATTRACTIVE STRATEGY TO ALLEVIATE REDUCTIVE STRESS AND SUPPORT ATP HOMEOSTASIS AS IT DEPENDS ON AN ENDOGENOUS ENZYME AND ONLY REQUIRES ADDITION OF RESPECTIVE NAPHTHOQUINONES. HOWEVER, NAPHTHOQUINONES CAPABLE OF BEING REDUCED BY NQO1 ARE EITHER NATURAL PRODUCTS OR SYNTHETIC REDOX SCAFFOLDS (E.G. IDEBENONE), AND WE CURRENTLY LACK INFORMATION ON ENDOGENOUS SUBSTRATES OF NQO1 AND ITS PLACE IN CELLULAR REDOX METABOLISM. TO CLOSE THIS KNOWLEDGE GAP, WE WILL USE ACTIVITY-BASED METABOLOMIC PROFILING WITH RECOMBINANT NQO1 TO IDENTIFY CELLULAR ENDOGENOUS METABOLITES THAT ARE INTERCONVERTED BY THIS ENZYME. NEXT, WE WILL RECONSTITUTE THE NQO1-MEDIATED ELECTRON TRANSFER WITH VARIOUS NAPHTHOQUINONES IN ISOLATED MITOCHONDRIA AND WILL STUDY THE BIOENERGETICS OF THIS NON-CANONICAL POINT OF ENTRY OF REDUCING EQUIVALENTS. THIS WILL ALLOW US TO RIGOROUSLY CHARACTERIZE NAPHTHOQUINONES AND RELATED REDOX-ACTIVE MOLECULES FOR THEIR ABILITY TO SAFELY BYPASS A CORRUPTED MITOCHONDRIAL ELECTRON TRANSPORT CHAIN WITHOUT INDUCING OXIDATIVE STRESS. OUR CURRENT APPROACH WILL, FOR THE FIRST TIME, ALLOW US TO IDENTIFY PHYSIOLOGICAL NQO1 SUBSTRATES AND HELP US BETTER RECONSTRUCT THE NQO1-MEDIATED ELECTRON TRANSFER. THIS WORK WILL ULTIMATELY PAVE THE WAY FOR DEVELOPING THERAPEUTIC MODALITIES THAT ARE BASED ON REDOX-ACTIVE SMALL MOLECULES THAT CAN ALLEVIATE REDUCTIVE STRESS.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $0 | 2/5/26 | ||
| Not listed | $529.7k | 9/22/23 |